{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:40:25Z","timestamp":1790314825773,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009]]},"abstract":"\n \n \n Infection with resistant pathogens can adversely affect clinical, microbiological and economic outcomes. New agents for the treatment of many such serious infections are acutely needed in hospital practice. Tigecycline is a novel glycylcycline antimicrobial for intravenous use. It has an expanded broad-spectrum antibacterial activity including multi-drug resistant pathogens, like methicillin-resistant\n Staphylococcus aureus<\/jats:italic>\n , vancomycin-resistant\n enterococci<\/jats:italic>\n , multi-drug resistant\n Streptococcus pneumoniae<\/jats:italic>\n , extended-spectrum \u03b2-lactamase-producing gram-negative bacteria and\n Acinetobacter baumannii<\/jats:italic>\n . Tigecycline however is not active against\n Proteus, Providencia<\/jats:italic>\n and\n Pseudomonas<\/jats:italic>\n species. Its currently approved indications include complicated skin and skin structure infections and complicated intra-abdominal infections. It has also been found to be effective for the treatment of community- as well as hospital-acquired and ventilator-associated pneumonia and bacteremia, sepsis with shock and urinary tract infections. Tigecycline appears to be a valuable treatment option for the management of superbugs, especially where conventional therapy has failed.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0022-3859.48443","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T23:35:16Z","timestamp":1235691316000},"page":"65-68","source":"Crossref","is-referenced-by-count":29,"title":["Tigecycline"],"prefix":"10.4103","volume":"55","author":[{"given":"M","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20240205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","article-title":"Tigecycline","volume":"56","author":"Pankey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R2-15-20240205","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-15-20240205","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)- mediaed ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-15-20240205","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152, 288) against various gram positive and gram negative bacteria","volume":"44","author":"van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-15-20240205","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.44.4.1085-1088.2000","article-title":"Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and resistant pneumococci","volume":"44","author":"Hoellman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-15-20240205","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clinthera.2006.08.011","article-title":"Tigecycline: A glycylcycline antimicrobial agent","volume":"28","author":"Doan","year":"2006","journal-title":"Clin Thers"},{"key":"R8-15-20240205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0924-8579(01)00355-7","article-title":"GAR-936 (9-t-butylglycylamidominocycline) susceptibility test development for streptococci, Haemophillus influenzae and Neisseria gonorrhoeae : Prelimnary guidelines and interpretive criteria","volume":"18","author":"Deshpande","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"R10-15-20240205","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2146\/ajhp050487","article-title":"Tigecycline: A new glycylcycline antimicrobial agent","volume":"63","author":"Kasbekar","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"R11-15-20240205","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind Phase 3 comparison study with vancomycin-aztreonam","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-15-20240205","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","article-title":"Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a Phase 3 randomised double-blind trial","volume":"9","author":"Sacchidanand","year":"2005","journal-title":"Int J Infect Dis"},{"key":"R13-15-20240205","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients","volume":"26","author":"Postier","year":"2004","journal-title":"Clin Ther"},{"key":"R14-15-20240205","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin-Structure Infections: Results of 2 Double-Blind Phase 3 Comparison Studies with Vancomycin-Aztreonam","volume":"41","author":"Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R15-15-20240205","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicentric trial of the efficacy and safety of tigecycline vs. imipenem\/ cilastatin in patients with complicated intra-abdominal infections","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"key":"R16-15-20240205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1179\/joc.2008.20.1.69","article-title":"A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics","volume":"20","author":"Kuti","year":"2008","journal-title":"J Chemother"},{"key":"R17-15-20240205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R18-15-20240205","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1592\/phco.27.7.980","article-title":"Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii","volume":"27","author":"Schafer","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R19-15-20240205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2008.04.009","article-title":"Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia","volume":"61","author":"Tanaseanu","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R20-15-20240205","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/jac\/dkm541","article-title":"Tigecycline for the treatment of patients with severe sepsis or septic shock: A drug use evaluation in a surgical intensive care unit","volume":"61","author":"Swoboda","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R21-15-20240205","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1128\/JCM.02494-07","article-title":"Treatment of recurrent urosepsis with tigecycline: A pharmacological perspective","volume":"46","author":"Curcio","year":"2008","journal-title":"J Clin Microbiol"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-200955010-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:18:09Z","timestamp":1787768289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-200955010-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.48443","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}